Key terms
About ROIV
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ROIV news
Today
7:50am ET
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Teladoc (TDOC) and Gilead Sciences (GILD)
Apr 24
12:21pm ET
Greenlight took long positions in HP, Penn Entertainment, Roivant Sciences in Q1
Apr 24
12:16pm ET
Greenlight bought ‘small long position’ in Roivant during Q1
Apr 24
12:14pm ET
Greenlight bought ‘small long position’ in Roivant during Q1
Apr 22
6:20am ET
Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)
Apr 17
2:00pm ET
Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
Apr 03
3:05pm ET
Moderna could owe $1B-$3B in royalties, says Jefferies
Apr 03
2:02pm ET
Roivant, Arbutus higher after ruling on COVID patent order
Apr 03
1:56pm ET
Jefferies sees Roivant rallying 5%-10% on today’s COVID patent order
Apr 03
8:11am ET
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
Apr 03
6:26am ET
Buy Rating Affirmed for Roivant Sciences Amid Brepocitinib Success and Strategic Share Repurchase Program
Apr 03
6:10am ET
Roivant Sciences price target raised to $18 from $17 at H.C. Wainwright
Apr 03
5:03am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Inari Medical (NARI) and Roivant Sciences (ROIV)
Apr 03
4:32am ET
Roivant Sciences price target raised to $15 from $14 at Deutsche Bank
Apr 02
4:10pm ET
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)
Apr 02
7:15am ET
Roivant Sciences board approves of repurchase program up to $1.5B
Apr 02
7:15am ET
Roivant Sciences announces NEPTUNE study met primary efficacy endpoint
Apr 01
4:55am ET
Sunrun to replace PGT Innovations in the S&P 600 at open on 4/1
Apr 01
4:55am ET
Roivant Sciences to replace Sunrun in the S&P 400 at open on 4/1
Mar 28
3:46pm ET
Roivant Sciences call volume above normal and directionally bullish
Mar 27
12:46pm ET
Roivant Sciences call volume above normal and directionally bullish
Mar 26
5:21pm ET
Sunrun to replace PGT Innovations in the S&P 600 at open on 4/1
Mar 26
5:20pm ET
Roivant Sciences to replace Sunrun in the S&P 400 at open on 4/1
Mar 21
8:18am ET
Tourmaline Bio might see weakness today after Roche MG data, says Truist
Mar 13
7:15am ET
TD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)
Mar 06
7:37am ET
TD Cowen Sticks to Their Buy Rating for Roivant Sciences (ROIV)
Feb 21
4:55am ET
Roivant Sciences management to meet with Cantor Fitzgerald
Feb 20
8:14am ET
Roivant Sciences management to meet with Cantor Fitzgerald
Feb 16
6:27am ET
5 Best Mid-Cap Stocks to Buy Now, According to Analysts – February 2024
Feb 15
1:17am ET
Buy Rating Affirmed for Roivant Sciences: Undervaluation and Promising Pipeline Drive Positive Outlook
Feb 14
7:21pm ET
Wolfe starts Roivant at Outperform, notes robust balance sheet
No recent press releases are available for ROIV
ROIV Financials
Key terms
Ad Feedback
ROIV Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ROIV Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
